MCID: SQM013
MIFTS: 64

Squamous Cell Carcinoma, Head and Neck malady

Genetic diseases, Rare diseases, Cancer diseases, Immune diseases categories

Aliases & Classifications for Squamous Cell Carcinoma, Head and Neck

About this section
Sources:
46OMIM, 30LifeMap Discovery®, 8Disease Ontology, 9diseasecard, 42NIH Rare Diseases, 21Genetics Home Reference, 44Novoseek, 48Orphanet, 22GTR, 32MedlinePlus, 61UMLS, 39NCIt, 33MeSH, 34MESH via Orphanet, 62UMLS via Orphanet
See all sources

Aliases & Descriptions for Squamous Cell Carcinoma, Head and Neck:

Name: Squamous Cell Carcinoma, Head and Neck 46 9
Squamous Cell Carcinoma of the Head and Neck 30 8 42 21 61
Head and Neck Squamous Cell Carcinoma 8 42 21 48
Hnscc 42 21 44 48
Squamous Cell Carcinoma of Head and Neck 48 22
Lymphoplasmacytic Leukemia 42 61
Small Lymphocytic Lymphoma 42 61
Squamous Cell Carcinoma, Head and Neck, Somatic 46
Squamous Cell Carcinomas of Head and Neck 8
Carcinoma, Squamous Cell of Head and Neck 42
B-Cell Chronic Lymphocytic Leukemia 42
B-Cell Chronic Lymphoid Leukemia 42
Lymphoplasmacytoid Immunocytoma 42
 
Carcinoma of the Head and Neck 8
B-Cell Malignancy, Low-Grade 61
Chronic Lymphocytic Leukemia 61
Lymphoma Small Lymphocytic 44
Head and Neck Carcinoma 8
Cancer of Head and Neck 61
Carcinoma of the Neck 8
Head and Neck Cancer 32
Cancer of Neck 61
Neck Carcinoma 61
Neck Cancer 44
Scchn 21
B-Cll 42


Classifications:

Orphanet: 48 
Rare tumors


Characteristics (Orphanet epidemiological data):

48

External Ids:

OMIM46 275355
Disease Ontology8 DOID:5520, DOID:1542
MeSH33 C535575
Orphanet48 67037
MESH via Orphanet34 C535575
UMLS via Orphanet62 C1168401

Summaries for Squamous Cell Carcinoma, Head and Neck

About this section
MedlinePlus:32 Head and neck cancer includes cancers of the mouth, nose, sinuses, salivary glands, throat, and lymph nodes in the neck. most begin in the moist tissues that line the mouth, nose and throat. symptoms include a lump or sore that does not heal a sore throat that does not go away trouble swallowing a change or hoarseness in the voice using tobacco or alcohol increases your risk. in fact, 85 percent of head and neck cancers are linked to tobacco use, including smoking and smokeless tobacco. if found early, these cancers are often curable. treatments may include surgery, radiation therapy, chemotherapy or a combination. treatments can affect eating, speaking or even breathing, so patients may need rehabilitation. nih: national cancer institute

MalaCards based summary: Squamous Cell Carcinoma, Head and Neck, also known as squamous cell carcinoma of the head and neck, is related to colorectal cancer and breast cancer, and has symptoms including autosomal recessive inheritanceand squamous cell carcinoma. An important gene associated with Squamous Cell Carcinoma, Head and Neck is PTEN (phosphatase and tensin homolog), and among its related pathways are p53 Signaling and p53 signaling pathway. The drugs mercaptopurine and chlorambucil and the compounds gw9662 and panitumumab have been mentioned in the context of this disorder. Affiliated tissues include b cells, lymph node and salivary gland, and related mouse phenotypes are hematopoietic system and tumorigenesis.

Disease Ontology:8 A head and neck carcinoma that has material basis in squamous cells that line the moist, mucosal surfaces inside the head and neck.

Genetics Home Reference:21 Squamous cell carcinoma is a cancer that arises from particular cells called squamous cells. Squamous cells are found in the outer layer of skin and in the mucous membranes, which are the moist tissues that line body cavities such as the airways and intestines. Head and neck squamous cell carcinoma (HNSCC) develops in the mucous membranes of the mouth, nose, and throat.

Description from OMIM:46 275355

Related Diseases for Squamous Cell Carcinoma, Head and Neck

About this section

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma, Head and Neck:



Diseases related to squamous cell carcinoma, head and neck

Symptoms for Squamous Cell Carcinoma, Head and Neck

About this section

Symptoms by clinical synopsis from OMIM:

275355

Clinical features from OMIM:

275355

HPO human phenotypes related to Squamous Cell Carcinoma, Head and Neck:

id Description Frequency HPO Source Accession
1 autosomal recessive inheritance HP:0000007
2 squamous cell carcinoma HP:0002860

Drugs & Therapeutics for Squamous Cell Carcinoma, Head and Neck

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Campath13 38 ALEMTUZUMAB Berlex Laboratories Approved May 2001
FDA Label: Campath
Malady that Drug Treats: Leukemia
Indications and Usage:13 LEMTRADA is a CD52-directed cytolytic monoclonal antibody indicated dizziness, abdominal pain, flushing, and vomiting. (6.1) for the treatment of patients with relapsing forms of multiple sclerosis; (MS).
DrugBank Targets:11 1. CAMPATH-1 antigen; 2. Low affinity immunoglobulin gamma Fc region receptor III-B; 3. Complement C1r subcomponent; 4. Complement C1q subcomponent subunit A; 5. Complement C1q subcomponent subunit B; 6. Complement C1q subcomponent subunit C; 7. Low affinity immunoglobulin gamma Fc region receptor III-A; 8. High affinity immunoglobulin gamma Fc receptor I; 9. Low affinity immunoglobulin gamma Fc region receptor II-a; 10. Low affinity immunoglobulin gamma Fc region receptor II-b; 11. Low affinity immunoglobulin gamma Fc region receptor II-c; ;
Mechanism of Action:13 
Target: CD52 antigen
Action: after binding, induces cell lysis
FDA: The precise mechanism by which alemtuzumab exerts its therapeutic effects in multiple; 490 sclerosis is unknown but is presumed to involve binding to CD52, a cell surface antigen; 491 present on T and B lymphocytes, and on natural killer cells, monocytes, and; 492 macrophages. Following cell surface binding to T and B lymphocytes, alemtuzumab; 493 results in antibody-dependent cellular cytolysis and complement-mediated lysis.
2
Erbitux13 38 CETUXIMAB Imclone, Bristol-Myers Squibb Approved February 2004
FDA Label: Erbitux
Malady that Drug Treats: Colorectal Cancer
Indications and Usage:13 Erbitux® is an epidermal growth factor receptor (EGFR) antagonist indicated; for treatment of:; Head and Neck Cancer; Locally or regionally advanced squamous cell carcinoma of the head; and neck in combination with radiation therapy. (1.1, 14.1); Recurrent locoregional disease or metastatic squamous cell carcinoma; of the head and neck in combination with platinum-based therapy with; 5-FU. (1.1, 14.1); Recurrent or metastatic squamous cell carcinoma of the head and neck; progressing after platinum-based therapy. (1.1, 14.1); Colorectal Cancer; K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as; determined by FDA-approved tests; in combination with FOLFIRI for first-line treatment,; in combination with irinotecan in patients who are refractory to; irinotecan-based chemotherapy,; as a single agent in patients who have failed oxaliplatin- and; irinotecan-based chemotherapy or who are intolerant to irinotecan.; (1.2, 5.7, 12.1, 14.2); Limitation of Use: Erbitux is not indicated for treatment of Ras-mutant; colorectal cancer. (5.7, 14.2)
DrugBank Targets:11 1. Epidermal growth factor receptor; 2. Low affinity immunoglobulin gamma Fc region receptor III-B; 3. Complement C1r subcomponent; 4. Complement C1q subcomponent subunit A; 5. Complement C1q subcomponent subunit B; 6. Complement C1q subcomponent subunit C; 7. Low affinity immunoglobulin gamma Fc region receptor III-A; 8. Complement C1s subcomponent; 9. High affinity immunoglobulin gamma Fc receptor I; 10. Low affinity immunoglobulin gamma Fc region receptor II-a; 11. Low affinity immunoglobulin gamma Fc region receptor II-b; 12. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:13 
Target: binding of epidermal growth factor (EGF) and other ligands to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1)
Action: inhibitor
FDA: The epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) is a transmembrane; glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases including EGFR,; HER2, HER3, and HER4. The EGFR is constitutively expressed in many normal epithelial; tissues, including the skin and hair follicle. Expression of EGFR is also detected in many human; cancers including those of the head and neck, colon, and rectum. ; ; ; Cetuximab binds specifically to the EGFR on both normal and tumor cells, and competitively; inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming; growth factor-alpha. In vitro assays and in vivo animal studies have shown that binding of; cetuximab to the EGFR blocks phosphorylation and activation of receptor-associated kinases,; resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix; metalloproteinase and vascular endothelial growth factor production. Signal transduction through; the EGFR results in activation of wild-type Ras proteins, but in cells with activating Ras somatic; mutations, the resulting mutant Ras proteins are continuously active regardless of EGFR; regulation.; In vitro, cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC) against certain; human tumor types. In vitro assays and in vivo animal studies have shown that cetuximab; inhibits the growth and survival of tumor cells that express the EGFR. No anti-tumor effects of; cetuximab were observed in human tumor xenografts lacking EGFR expression. The addition of; cetuximab to radiation therapy or irinotecan in human tumor xenograft models in mice resulted; in an increase in anti-tumor effects compared to radiation therapy or chemotherapy alone.
3
Ethyol13 AMIFOSTINE Alza Approved December 8, 1995
FDA Label: Ethyol
Malady that Drug Treats: ovarian cancer
Indications and Usage:13 ETHYOL (amifostine) is indicated to reduce the cumulative renal toxicity associated with; repeated administration of cisplatin in patients with advanced ovarian cancer.; ETHYOL is indicated to reduce the incidence of moderate to severe xerostomia in patients; undergoing post-operative radiation treatment for head and neck cancer, where the radiation; port includes a substantial portion of the parotid glands (see Clinical Studies).; For the approved indications, the clinical data do not suggest that the effectiveness of cisplatin based; chemotherapy regimens or radiation therapy is altered by ETHYOL. There are at present only limited; data on the effects of ETHYOL on the efficacy of chemotherapy or radiotherapy in other settings.; ETHYOL should not be administered to patients in other settings where chemotherapy can produce a; significant survival benefit or cure, or in patients receiving definitive radiotherapy, except in the; context of a clinical study (see WARNINGS).
DrugBank Targets:11 1. Ectonucleotide pyrophosphatase/phosphodiesterase family member 1; 2. Alkaline phosphatase, placental-like
Mechanism of Action:13 
Target: -
Action: -
FDA: -
4
Taxotere13 38 DOCETAXEL Rhone Poulenc Rorer Approved May 1996
FDA Label: Taxotere
Malady that Drug Treats: breast cancer
Indications and Usage:13 TAXOTERE is a microtubule inhibitor indicated for:; Breast Cancer (BC): single agent for locally advanced or metastatic BC; after chemotherapy failure; and with doxorubicin and; cyclophosphamide as adjuvant treatment of operable node-positive BC; (1.1); Non-Small Cell Lung Cancer (NSCLC): single agent for locally; ; advanced or metastatic NSCLC after platinum therapy failure; and; ; with cisplatin for unresectable, locally advanced or metastatic; untreated NSCLC (1.2); ; Hormone Refractory Prostate Cancer (HRPC): with prednisone in; androgen independent (hormone refractory) metastatic prostate cancer; (1.3); Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for; untreated, advanced GC, including the gastroesophageal junction (1.4); Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN):; with cisplatin and fluorouracil for induction treatment of locally; advanced SCCHN (1.5)
DrugBank Targets:11 1. Tubulin beta-1 chain; 2. Apoptosis regulator Bcl-2; 3. Microtubule-associated protein 2; 4. Microtubule-associated protein 4; 5. Microtubule-associated protein tau; 6. Nuclear receptor subfamily 1 group I member 2
Mechanism of Action:13 
Target: free tubulin
Action: promoter of assembly
FDA: Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is; essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the; assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. This; leads to the production of microtubule bundles without normal function and to the stabilization of; microtubules, which results in the inhibition of mitosis in cells. Docetaxel s binding to microtubules; does not alter the number of protofilaments in the bound microtubules, a feature which differs from most; spindle poisons currently in clinical use.
5
Zydelig13 38 IDELALISIB Gilead Approved July 2014
FDA Label: Zydelig
Malady that Drug Treats: relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma
Indications and Usage:13 Zydelig is a kinase inhibitor indicated for the treatment of patients with:; Relapsed chronic lymphocytic leukemia (CLL), in combination with; rituximab, in patients for whom rituximab alone would be considered; appropriate therapy due to other co-morbidities. (1.1); Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients; who have received at least two prior systemic therapies. (1.2); Relapsed small lymphocytic lymphoma (SLL) in patients who have; received at least two prior systemic therapies. (1.3); Accelerated approval was granted for FL and SLL based on overall; response rate. Improvement in patient survival or disease related; symptoms has not been established. Continued approval for these; indications may be contingent upon verification of clinical benefit in; confirmatory trials.
DrugBank Targets:11 1. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (P110´)
Mechanism of Action:13 
Target: PI3K´ kinase
Action: inhibitor
FDA: Idelalisib is an inhibitor of PI3K´ kinase, which is expressed in normal and malignant Bcells.; Idelalisib induced apoptosis and inhibited proliferation in cell lines derived from; malignant B-cells and in primary tumor cells. Idelalisib inhibits several cell signaling; pathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5; signaling, which are involved in trafficking and homing of B-cells to the lymph nodes and; bone marrow. Treatment of lymphoma cells with idelalisib resulted in inhibition of; chemotaxis and adhesion, and reduced cell viability.

Drug clinical trials:

Search ClinicalTrials for Squamous Cell Carcinoma, Head and Neck

Search NIH Clinical Center for Squamous Cell Carcinoma, Head and Neck

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Squamous Cell Carcinoma, Head and Neck

About this section

Genetic tests related to Squamous Cell Carcinoma, Head and Neck:

id Genetic test Affiliating Genes
1 Squamous Cell Carcinoma of the Head and Neck22

Anatomical Context for Squamous Cell Carcinoma, Head and Neck

About this section

MalaCards organs/tissues related to Squamous Cell Carcinoma, Head and Neck:

31
B cells, Lymph node, Salivary gland, Skin, Breast, Liver, T cells, Endothelial

Animal Models for Squamous Cell Carcinoma, Head and Neck or affiliated genes

About this section

MGI Mouse Phenotypes related to Squamous Cell Carcinoma, Head and Neck:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053978.3EGFR, PTEN, TNFRSF10B, ING1
2MP:00020068.0EGFR, PTEN, TNFRSF10B, ING1

Publications for Squamous Cell Carcinoma, Head and Neck

About this section

Variations for Squamous Cell Carcinoma, Head and Neck

About this section

UniProtKB/Swiss-Prot genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

63
id Symbol AA change Variation ID SNP ID
1ING1p.Ala335AspVAR_017420
2ING1p.Cys358SerVAR_017421
3ING1p.Asn359SerVAR_017422
4ING3p.Asp20GlyVAR_021263
5PTENp.Ala121GlyVAR_018103

Clinvar genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

5 (show all 11)
id Gene Variation Type Significance SNP ID Assembly Location
1NM_005228.3(EGFR): c.2327G> A (p.Arg776His)single nucleotide variantdrug responsers483352806GRCh37Chr 7, 55249029: 55249029
2EGFRNM_005228.3(EGFR): c.2471G> A (p.Gly824Asp)single nucleotide variantdrug responsers483352808GRCh38Chr 7, 55191720: 55191720
3EGFRNM_005228.3(EGFR): c.2188C> G (p.Leu730Val)single nucleotide variantdrug responsers121913434GRCh37Chr 7, 55242418: 55242418
4NM_005228.3(EGFR): c.2393T> A (p.Leu798His)single nucleotide variantdrug responsers483352807GRCh38Chr 7, 55181402: 55181402
5EGFRNM_005228.3(EGFR): c.2176G> A (p.Val726Met)single nucleotide variantdrug responsers483352805GRCh37Chr 7, 55241728: 55241728
6EGFRNM_005228.3(EGFR): c.2155G> C (p.Gly719Arg)single nucleotide variantLikely pathogenic, drug responsers28929495GRCh37Chr 7, 55241707: 55241707
7TNFRSF10BTNFRSF10B, 2-BP INSinsertionPathogenic
8PTENNM_000314.4(PTEN): c.362C> G (p.Ala121Gly)single nucleotide variantPathogenicrs121909237GRCh37Chr 10, 89692878: 89692878
9ING1NM_198217.2(ING1): c.512G> C (p.Cys171Ser)single nucleotide variantPathogenicrs121909250GRCh37Chr 13, 111372083: 111372083
10ING1NM_198217.2(ING1): c.515A> G (p.Asn172Ser)single nucleotide variantPathogenicrs121909251GRCh37Chr 13, 111372086: 111372086
11ING1NM_198217.2(ING1): c.443C> A (p.Ala148Asp)single nucleotide variantPathogenicrs121909252GRCh37Chr 13, 111372014: 111372014

Cosmic variations for Squamous Cell Carcinoma, Head and Neck:

6
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
128675CDKN2Aupper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma1

Expression for genes affiliated with Squamous Cell Carcinoma, Head and Neck

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Squamous Cell Carcinoma, Head and Neck patients vs. healthy controls: 30 (show all 18)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1ARG1arginase 1Blood+11.630.000
2IFI27interferon, alpha-inducible protein 27Blood+5.470.000
3OTOFotoferlinBlood+5.250.000
4TMPRSS11Btransmembrane protease, serine 11BHead Mesenchyme-4.810.000
5CRISP3cysteine-rich secretory protein 3Head Mesenchyme-4.480.000
6MALmal, T-cell differentiation proteinHead Mesenchyme-4.390.000
7IFIT1interferon-induced protein with tetratricopeptide repeats 1Blood+4.220.000
8LINC00661long intergenic non-protein coding RNA 661Blood+4.150.000
9SIGLEC1sialic acid binding Ig-like lectin 1, sialoadhesinBlood+4.120.000
10CRNNcornulinHead Mesenchyme-4.000.000
11RSAD2radical S-adenosyl methionine domain containing 2Blood+3.810.000
12IFI44Linterferon-induced protein 44-likeBlood+3.580.000
13KRT4keratin 4Head Mesenchyme-3.410.000
14USP41ubiquitin specific peptidase 41Blood+3.400.000
15CLCA4chloride channel accessory 4Head Mesenchyme-3.310.000
16HESX1HESX homeobox 1Blood+3.220.000
17TGM3transglutaminase 3Head Mesenchyme-3.080.000
18IFIT3interferon-induced protein with tetratricopeptide repeats 3Blood+3.080.000

Search GEO for disease gene expression data for Squamous Cell Carcinoma, Head and Neck.

Pathways for genes affiliated with Squamous Cell Carcinoma, Head and Neck

About this section

Pathways related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show all 14)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.6TNFRSF10B, PTEN
2
Show member pathways
DNA damage response36
9.6TNFRSF10B, PTEN
39.5PTEN, ING1
49.2EGFR, PTEN
5
Show member pathways
Signal transduction PTEN pathway59
9.2EGFR, PTEN
6
Show member pathways
PLK2 and PLK4 events36
Polo-like kinase signaling events in the cell cycle36
9.2EGFR, PTEN
79.2EGFR, PTEN
8
Show member pathways
Translation Non genomic rapid action of Androgen Receptor59
9.2EGFR, PTEN
99.2EGFR, PTEN
109.2EGFR, PTEN
11
Show member pathways
8.8TNFRSF10B, PTEN, EGFR
12
Show member pathways
8.8EGFR, PTEN, TNFRSF10B
138.8EGFR, PTEN, TNFRSF10B
14
Show member pathways
8.8TNFRSF10B, PTEN, EGFR

Compounds for genes affiliated with Squamous Cell Carcinoma, Head and Neck

About this section

Compounds related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show all 30)
idCompoundScoreTop Affiliating Genes
1gw966244 2811.0PTEN, TNFRSF10B
2panitumumab44 50 1111.6EGFR, PTEN
3taxane449.6PTEN, EGFR
4cetuximab44 50 1111.6EGFR, PTEN
5bicalutamide44 60 1111.6PTEN, EGFR
6erlotinib44 50 1111.6EGFR, PTEN
7topotecan44 1110.5EGFR, TNFRSF10B
8suberoylanilide hydroxamic acid449.5TNFRSF10B, EGFR
9trastuzumab44 50 1111.5PTEN, EGFR
10oxaliplatin44 50 1111.5EGFR, TNFRSF10B
11amiloride44 28 1111.5EGFR, TNFRSF10B
12flavopiridol44 1110.5EGFR, TNFRSF10B
13etoposide44 50 60 1112.4PTEN, TNFRSF10B, ING1
14gefitinib44 50 1111.4PTEN, EGFR
15celecoxib44 60 28 50 24 1114.4EGFR, TNFRSF10B
16irinotecan44 50 1111.3TNFRSF10B, EGFR
17adpribose449.3EGFR, TNFRSF10B
18curcumin449.2TNFRSF10B, EGFR
19bortezomib44 50 1111.2PTEN, TNFRSF10B, EGFR
20gemcitabine44 50 1111.2PTEN, TNFRSF10B, EGFR
21mg 13244 6010.2PTEN, EGFR, TNFRSF10B
225fluorouracil449.1PTEN, TNFRSF10B, EGFR
23imatinib44 50 1111.1EGFR, PTEN
24doxorubicin44 50 1111.1PTEN, TNFRSF10B, EGFR
25cycloheximide449.0TNFRSF10B, EGFR, PTEN
26vegf448.9EGFR, TNFRSF10B, PTEN
27estrogen448.7EGFR, PTEN, ING1
28paclitaxel44 50 1110.7ING1, TNFRSF10B, PTEN, EGFR
29cisplatin44 50 60 1111.6EGFR, TNFRSF10B, PTEN, ING1
30retinoic acid44 249.5EGFR, PTEN, TNFRSF10B

GO Terms for genes affiliated with Squamous Cell Carcinoma, Head and Neck

About this section

Cellular components related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nucleusGO:00056347.6EGFR, FAT2, PTEN, ING3, ING1

Biological processes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1learning or memoryGO:00076119.3EGFR, PTEN
2fibroblast growth factor receptor signaling pathwayGO:00085439.2EGFR, PTEN
3cellular response to mechanical stimulusGO:00712609.2EGFR, TNFRSF10B
4phosphatidylinositol-mediated signalingGO:00480159.1PTEN, EGFR
5cell surface receptor signaling pathwayGO:00071668.9EGFR, TNFRSF10B

Molecular functions related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1methylated histone residue bindingGO:00350649.3ING3, ING1

Sources for Squamous Cell Carcinoma, Head and Neck

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet